Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Peer Reviewed Medical Research Program

Technology/Therapeutic Development Award

Funding Opportunity Number: W81XWH-10-PRMRP-TTDA

TABLE OF CONTENTS

I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

Appropriations History: The Peer Reviewed Medical Research Program (PRMRP) was established in 1999 to provide support for military health-related research of exceptional scientific merit. Appropriations for the PRMRP from Fiscal Year 1999 (FY99) through FY09 (excluding FY07, in which no appropriation was made) totaled $444.5 million (M). The FY10 appropriation is $50M.

FY10 Objectives: The vision of the FY10 PRMRP is to identify and fund the best medical research to protect and support warfighters, veterans, and all beneficiaries, and to eradicate diseases that impact these populations. The PRMRP challenges the scientific and clinical communities to address one of the FY10 congressionally directed topic areas with original ideas that foster new directions in basic science and translational research; novel product development leading to improved therapeutic or diagnostic tools, or improvements in clinical policies/guidelines; or clinical trials that address an immediate clinical need. The PRMRP seeks applications in laboratory, clinical, behavioral, and epidemiologic research, as well as public health and policy; environmental sciences; nursing; occupational health; alternative therapies; ethics; economics; and strategic research, such as studies designed to shape the development of or to validate clinical policy or guidance. Interdisciplinary and integrative health approaches are welcomed.

B. FY10 PRMRP Topic Areas

All applications for PRMRP funding must specifically and clearly address at least one of the topic areas as directed by Congress, and must have direct relevance to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population. If the proposed research has no relevance to currently advertised PRMRP topic areas, the Government reserves the right to administratively withdraw the application. The Government also reserves the right to reassign the application's topic area if submitted under an inappropriate topic area. The FY10 PRMRP topic areas as provided by Congress are listed below.

Chronic Migraine and Post-traumatic Headache

Dystonia

Drug Abuse

Epilepsy

Fragile X Syndrome

Inflammatory Bowel Disease

Interstitial Cystitis

Listeria vaccine for infectious disease

Lupus

Mesothelioma

Neuroblastoma

Osteoporosis and related bone disease

Paget's Disease

Pheochromocytoma

Polycystic Kidney Disease

Post-traumatic Osteoarthritis

Scleroderma

Social Work Research

Tinnitus

C. Award Description

The PRMRP Technology/Therapeutic Development Award mechanism was first offered in FY08 as the Advanced Technology/Therapeutic Development Award. Since then, 119 Technology/Therapeutic Development Award proposals have been received, and 6 have been recommended for funding**.**

This award is product-driven and is intended to provide support for the translation of promising preclinical findings into products for clinical applications in at least one of the congressionally directed FY10 PRMRP topic areas. Products in development should be responsive to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population. All applications must specifically and clearly address the military relevance of the proposed research. Collaboration with military and/or U.S Department of Veterans Affairs (VA) researchers and/or clinicians is encouraged.

The product(s) to be developed may be pharmacologic agents (drugs or biologicals), devices, and/or clinical guidance. The Principal Investigator (PI) must provide a transition plan (including potential funding and resources) showing how the product will progress to clinical trials and/or delivery to the military or civilian market after the completion of the PRMRP award.

Examples of the types of research that may be supported include, but are not limited to:

- Collection and analysis of data for developing and validating clinical guidance
- Testing new therapeutic modalities (agents, delivery systems, chemical modification of lead compounds) using established or validated novel preclinical systems
- Designing and implementing full-scale, pilot Good Manufacturing Practice (GMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials
- Developing pharmacologic agents through adsorption, distribution, metabolism, excretion, and toxicity (ADMET) phase
- Developing pharmacologic agents to Investigational New Drug (IND) stage for initiation of Phase I clinical trials
- Developing prototype devices for diagnosis or treatment to Investigational Device Exemption (IDE) stage for initiation of Phase I clinical trials
- Optimizing diagnostic or treatment devices for field deployment

Applications must include data relevant to the FY10 PRMRP topic area(s) addressed that support the rationale for the proposed study. These data may be unpublished and/or from the published literature.

This award may not be used to conduct clinical trials. PIs seeking funding for a clinical trial should apply to the FY10 PRMRP Clinical Trial Award mechanism.

Use of human subjects and human biological substances: All DOD-funded research involving human subjects and human biological substances must be reviewed and approved by the USAMRMC Office of Research Protections (ORP), Human Research Protection Office (HRPO), in addition to local Institutional Review Boards (IRBs). The HRPO is mandated to comply with specific laws and directives governing all research involving human subjects that is conducted or supported by the DOD. These laws and directives are rigorous and detailed, and will require information in addition to that supplied to the local review board. Allow a minimum of 6 months for regulatory review and approval processes for studies involving human subjects.

Encouraged DOD alignment: Relevance to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population is a key feature of this award. Therefore, PIs are strongly encouraged to collaborate, integrate, and/or align their research projects with military and/or VA research laboratories and programs. The following websites may be useful in identifying information about ongoing DOD areas of research interest within the FY10 PRMRP topic areas:

Air Force Research Laboratory
http://www.wpafb.af.mil/afrl

Congressionally Directed Medical Research Programs
http://cdmrp.army.mil

Defense Advanced Research Projects Agency
http://www.darpa.mil/

Defense Technical Information Center
http://www.dtic.mil

Naval Health Research Center
http://www.med.navy.mil/sites/nhrc

Navy and Marine Corps Public Health Center
http://www-nmcphc.med.navy.mil/

Office of Naval Research
http://www.onr.navy.mil/

Office of the Under Secretary of Defense for Acquisition, Technology and Logistics

http://www.acq.osd.mil/

U.S. Army Medical Research Acquisition Activity

http://www.usamraa.army.mil

U.S. Army Medical Research and Materiel Command
https://mrmc.amedd.army.mil

U.S. Army Research Laboratory
http://www.arl.army.mil

U.S. Naval Research Laboratory
www.nrl.navy.mil

U.S. Department of Veterans Affairs, Office of Research and Development
www.research.va.gov

D. Eligibility

PIs at or above the level of Assistant Professor (or equivalent) are eligible to submit applications. Refer to General Application Instructions, Appendix 1, for general eligibility information.

E. Funding

- The maximum period of performance is 4 years.
- The maximum allowable funding for the entire period of performance is $1.7M in direct costs.

- The applicant may request the entire maximum direct cost amount for a project that may be less than the maximum 4-year period of performance.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum direct cost. In addition to the direct costs, indirect costs may be proposed in accordance with the organization's negotiated rate agreement.

Within the guidelines provided in the General Application Instructions, funds can cover:

- Salary
- Research supplies
- Equipment
- Clinical research costs (Clinical trials are not supported)
- Travel between collaborating organizations
- Travel costs of up to $1,800 per year to attend scientific/technical meetings
- Other direct costs as described in the General Application Instructions for the Detailed Budget and Justification

In addition, each PI must request travel funds, up to $1,800, to attend one Military Health Research Forum (MHRF) during the award period of performance. The MHRF is a CDMRP-sponsored meeting that is typically held every 2-3 years.

The Office of the Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $5.1M of the $50M FY10 PRMRP appropriation to fund approximately 2 Technology/Therapeutic Development Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.

F. Award Administration

Quarterly technical progress reports may be required if the proposed research project includes recruitment of human subjects. Awards will be made approximately 4 to 6 months after receiving a funding notification letter, but no later than September 30, 2011. Refer to the General Application Instructions, Appendix 4, for general award administration information.

II. TIMELINE FOR SUBMISSION AND REVIEW

- **Pre-application Submission Deadline: 5:00 p.m. Eastern time (ET), April 22, 2010**
- **Application Submission Deadline: 11:59 p.m. ET, May 13, 2010**
- **Scientific Peer Review: September 2010**
- **Programmatic Review: December 2010**

Application submissions will not be accepted unless the pre-application process is completed by the pre-application deadline.

III. SUBMISSION PROCESS

Submission is a two-step process requiring both (1) pre-application submission through the CDMRP eReceipt system (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

PIs and organizations identified in the application should be the same as those identified in the pre-application. If a change in PI or organization is necessary after submission of the pre-application, the PI must contact the eReceipt help desk at help@cdmrp.org or 301-682-5507.

A. Step 1 – Pre-Application Components

All pre-application components must be submitted through the CDMRP eReceipt system by ***5:00 p.m. ET on the deadline***.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt system by separate tabs: (Refer to the General Application Instructions for additional information on pre-application submission.)

- **Proposal Information – Tab 1**
- **Proposal Contacts – Tab 2**
- **Collaborators and Conflicts of Interest – Tab 3**
- **Required Files – Tab 4**

  Letter of Intent (LOI) Narrative (one-page limit): Provide a brief description of the research to be conducted. LOI Narratives are used for program planning purposes only (e.g., reviewer recruitment) and ***will not be reviewed*** during either the peer or programmatic review sessions.
- **Submit Pre-application – Tab 5**
- **Other Documents Tab**

  Not applicable.

B. Step 2 – Application Components

Applications are submitted by the Authorized Organizational Representative (AOR) through Grants.gov (http://www.grants.gov/). Applications must be submitted **by *11:59 p.m. ET on the deadline.***

Each application submission must include the completed application package of forms and attachments identified in Grants.gov for this Program Announcement/Funding Opportunity.

The Grants.gov application package consists of the following components (Refer to the General Application Instructions, Section II.B., for additional information on application submission):

1. SF 424 (R&R) Application for Federal Assistance Form: Refer to the General Application Instructions, Section II.B., for detailed information.

2. Attachments Form

- **Attachment 1: Project Narrative (15-page limit):** Upload as "ProjectNarrative.pdf."

  Describe the proposed project in detail using the outline below. Applications must include preliminary data relevant to the FY10 PRMRP topic area(s) to be addressed and the proposed research project.

  - Background: Present the ideas and reasoning behind the proposed research, to include relevant literature citations. Describe previous experience most pertinent to this proposal.
  - Hypothesis or Objective: State the hypothesis to be tested or the objective to be reached.
  - Specific Aims: Concisely explain the project's specific aims. These aims should agree with the primary aims and associated tasks described in the Statement of Work. If the proposed work is part of a larger study, present only aims that this DOD award would fund.
  - Research Strategy: Describe the experimental design, methods, and analyses including appropriate controls in sufficient detail for analysis. Address potential problem areas and present alternative methods and approaches. If human subjects or human biological samples will be used, include a detailed plan for the recruitment of subjects or the acquisition of samples. ***This award may not be used to conduct clinical trials.***

- **Attachment 2: Supporting Documentation.** Start each document on a new page. Combine and upload as a single file named "Support.pdf." If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. ***Each component has no page limit unless otherwise noted.***

  - References Cited: List all relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate). The inclusion of Internet URLs to references is encouraged.
  - List of Acronyms and Symbols: Provide a list of acronyms and symbols (e.g., PCR = polymerase chain reaction).
  - Facilities, Existing Equipment, and Other Resources: Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the US Army Medical Research and Materiel Command (USAMRMC). Indicate if Government-owned facilities or equipment are proposed for use. Reference

should be made to the original or present contract under which the facilities or equipment items are now accountable. There is no form for this information.

- Publications and/or Patent Abstracts (five-document limit): Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.
- Letters of Organizational Support: Provide a letter (or letters if applicable), signed by the Department Chair or appropriate organization official, reflecting the laboratory space, equipment, and other resources available for the project. If the PI is a practicing clinical physician, the institution must clearly demonstrate a commitment to the clinician's research.
- Letters of Collaboration (if applicable): Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the resources necessary for the proposed work.
- Intellectual and Material Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as "TechAbs.pdf."

  State the FY10 PRMRP topic area addressed by the proposed research project. Describe the proposed research project including the following elements: Background, hypothesis or objective, study design, and the relevance of the project to the FY10 PRMRP topic area(s).

- **Attachment 4: Public Abstract (one-page limit):** Upload as "PublicAbs.pdf."

  State the FY10 PRMRP topic area addressed by the proposed research project. Clearly describe, in a manner readily understood by lay persons, the central critical problem or question to be addressed, the innovative aspect of the research, and the relevance of the project to the FY10 PRMRP topic area(s). It should be distinct and separate from the technical abstract. Do not duplicate the technical abstract; the public abstract is used by consumer peer reviewers along with other components of the application package.

- **Attachment 5: Statement of Work (SOW) (three-page limit):** Upload as "SOW.pdf." Refer to the General Application Instructions, Section II.B., for detailed information.

- **Attachment 6: Detailed Budget and Justification (no page limit):** Upload as "Budget.pdf." Use the Detailed Budget and Justification form (available for download on the Full Announcement page in Grants.gov). Refer to the General Application Instructions, Section II.B., for detailed information.

- **Attachment 7: Subaward Detailed Budget and Justification (if applicable) (no page limit):** Use a separate Detailed Budget and Justification form for each subaward budget. Combine into a single file and upload as "SubBudgets.pdf." Refer to the General Application Instructions, Section II.B., for detailed information.

- **Attachment 8: Impact Statement (one-page limit):** Upload as "Impact.pdf."

  Explain how the product in development (pharmacologic agent, device, and/or clinical guidance) is important and relevant to improving diagnosis, patient care, and/or quality of life in the FY10 PRMRP topic area(s) addressed.

  Describe the short-term impact: Detail the anticipated outcome(s)/product(s) (intellectual and/or tangible) that will be directly attributed to the results of the proposed research.

  Describe the long-term impact: Articulate the vision for the final product that is in development. Describe the anticipated long-term gains from this research course, and compare to pharmacologic agents, devices, and/or clinical guidance currently available, if applicable.

- **Attachment 9: Transition Plan (one-page limit):** Upload as "Transition.pdf."

  Provide information on the methods and strategies proposed to move the product to clinical trials and/or delivery to the military or civilian market after the completion of the PRMRP award. The plan should include details of funding sources, collaborations, and other resources that will be used to provide this continuity of development.

- **Attachment 10: Military Relevance Statement (one-page limit):** Upload as "MilRel.pdf."

  Demonstrate how the proposed study is responsive to the health care needs of the Armed Forces, their family members, and/or the U.S. veteran population. If active duty military, military families, or veteran population(s) will be used in the proposed research project, describe the population(s), the appropriateness of the population(s) for the proposed study, and the feasibility of using the population. If a non-military population will be used for the proposed research project, explain how the population simulates the targeted population (i.e., Armed Forces, their family members, and/or the U.S. veteran population). Show how the proposed study complements ongoing DOD areas of research interest in the topic area addressed. Describe how the study design will replicate field conditions, if applicable, for the selected FY10 PRMRP topic area(s).

- **Attachment 11: Human subject plan (if applicable) (two-page limit)**: Upload as "HumSub.pdf."

  Describe the availability of the proposed study population, whether the PI and/or key personnel of the proposal currently have access to this population, and how access to potential participants will be coordinated. Outline the recruitment strategy and past successes for recruiting similar populations

  Attachment 12: Approval for access to military populations (if applicable) (one-page limit): Upload as "MilPop.pdf."

  A letter of support, signed by the lowest ranking person with approval authority, should be included for studies involving active duty military, military families, or veterans; military-controlled study materials; databases; and/or restricted facilities (e.g., biological or chemical containment facilities).

3. Research & Related Senior/Key Person Profile (Expanded) Form: Refer to the General Application Instructions, Section II.B., for detailed information.

- PI Biographical Sketch (four-page limit): Upload as "Biosketch_LastName.pdf."
- PI Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."
- Key Personnel Biographical Sketches (four-page limit each): Upload as "Biosketch_LastName.pdf."
- Key Personnel Current/Pending Support (no page limit): Upload as "Support_LastName.pdf."

4. Project/Performance Site Location(s) Form: Refer to the General Application Instructions, Section II.B., for detailed information.

IV. INFORMATION FOR APPLICATION REVIEW

A. Application Review and Selection Overview

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a scientific peer review of applications against established criteria for determining scientific merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Commanding General, USAMRMC, based on scientific merit, the overall goals of the program, and specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP may be found at http://cdmrp.army.mil/fundingprocess

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a nondisclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization's application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

B. Review Criteria

1. Peer Review: All applications will be evaluated according to the following criteria, which are of equal importance:

- **Feasibility**
  - How the PI acknowledges potential problems and addresses alternative approaches.
  - How the background and expertise of the PI and other key personnel demonstrate their ability to perform the proposed work.
  - How the proposed methods are appropriate to test the hypothesis or achieve the objectives.
  - If applicable, whether the human subjects plan is appropriate.
  - Whether the proposed research can be completed in the proposed period of performance.
- **Impact**
  - How the anticipated short-term outcome(s)/product(s) (intellectual and/or tangible) of the proposed research project in the FY10 PRMRP topic area(s) addressed will impact the research field, patient care, and/or quality of life.
  - Whether the proposed research project, if successful, will develop a product that is important and relevant to improving diagnosis, patient care, and/or quality of life.
  - How well the final envisioned product compares to pharmacologic agents, devices, and/or clinical guidance currently available, if applicable.
- **Research Strategy**
  - How the scientific rationale supports the project as demonstrated by a critical review and analysis of the literature, preliminary data, and logical reasoning.
  - How the hypotheses or objectives, aims, experimental design, methods, and analyses are developed.
  - How adequate is the statistical plan, including sample size projections and power analysis, for the study and all proposed correlative studies.
  - How consistent is the data analysis plan with the study objectives.
  - If applicable, how well constructed is the clinical study, and its appropriateness for the study objectives (to include the appropriateness of the study population).
- **Transition Plan**
  - Whether an established plan for bringing the product to clinical trials or delivery was well developed.
  - Whether the PI has or can secure additional funding needed to bring the product to clinical trials or delivery.

- How well the resources proposed to bring the product to delivery support the likelihood of success.

The following will not be individually scored, but may impact the overall evaluation of the application:

- **Personnel**
  - How the levels of effort by the PI and other key personnel are appropriate to ensure success of this project.
- **Environment**
  - The appropriateness of the scientific environment for the proposed research.
  - How the research requirements are supported adequately by the availability of and accessibility to facilities and resources (including collaborative arrangements).
  - The quality and extent of institutional support.
- **Budget**
  - Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.
- **Application Presentation**
  - How the writing and components of the application influenced the review.

2. Programmatic Review: The following equally weighted criteria are used by programmatic reviewers to make funding recommendations.

- **Adherence to the intent of the award mechanism**
  - Whether the proposed research project is focused on development of a product (pharmacologic agent, device, or clinical guidance).
  - Whether the transition plan for the product was sufficiently detailed to indicate that the PI understands how to move the product of this award to a clinical trial, to a manufacturer, and/or delivery to the military or civilian market and is capable of accomplishing the transition.
- **Military relevance**
  - How well the proposed research project is responsive to documented health care needs of the Armed Forces, their family members, and/or the U.S. veteran population.
  - Whether the PI has access to the proposed study population (active duty military, military families, veteran population(s), and/or non-military), if applicable, and how this population is appropriate for the proposed study objectives.

- How the non-military population to be used for the proposed research project simulates the targeted military population (i.e., Armed Forces, their family members, and/or the U.S. veteran population), if applicable.
- How the proposed study complements ongoing DOD areas of research interest.

- **Program portfolio composition**
  - Whether the proposed study specifically addresses research areas that are underrepresented in the existing PRMRP portfolio (Click here to search PRMRP awards http://cdmrp.army.mil/search.aspx) and would therefore add to the overall balance of research and development efforts in the existing portfolio.
- **Ratings and evaluations of the peer reviewers**
  - Whether the application was assessed as scientifically meritorious with the strengths identified outweighing the weaknesses.
- **Relative impact**
  - FY10 PRMRP applications will be compared to identify those projects with the highest relative potential impact.
- **Relevance to program objectives**
  - Whether the proposed research project supports the mission of the PRMRP to "Provide support for military health-related research of exceptional scientific merit."

V. ADMINISTRATIVE ACTIONS

After receipt of applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).

B. Modifications

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative.
- Documents not requested will be removed.
- Following the application deadline, you may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section V-A, Rejection). The missing documents must be provided by 5:00 p.m. ET on

the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.

C. Withdrawal

The following may result in administrative withdrawal of the application:

- FY10 PRMRP Joint Programmatic Review Panel) (JPRP) member(s) is found to be involved in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY10 PRMRP JPRP members may be found at http://cdmrp.army.mil/prmrp/panels/panel10
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the detailed budget form exceed maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs with the exception of links to published references.
- The PI does not meet the eligibility criteria as described in this Program Announcement/Funding Opportunity.
- The proposed research is or contains a clinical trial.
- The proposed research is not relevant to any of the congressionally directed FY10 PRMRP topic areas.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be requested to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.

VI. CONTACT INFORMATION

A. CDMRP Program Announcement Help Desk: Questions related to Program Announcement/Funding Opportunity content or submission requirements should be directed to the CDMRP Program Announcement help desk, which is available Monday through Friday from 7:30 a.m. to 4:00 p.m. ET. Submit questions as early as possible. Response times will vary depending upon the volume of inquiries. Every effort will be made to answer questions within 5 working days.

Phone: 301-619-7079
Email: cdmrp.pa@amedd.army.mil

B. CDMRP eReceipt System Help Desk: Questions related to the submission of the pre-application through the eReceipt system should be directed to the CDMRP eReceipt system help desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET.

Phone: 301-682-5507
Email: help@cdmrp.org

C. Grants.gov Contact Center: Questions related to application submission through the Grants.gov portal should be directed to Grants.gov help desk, which is available 24 hours a day, 7 days a week. Please note that the CDMRP Program Announcement and eReceipt system help desks are unable to provide technical assistance regarding Grants.gov submissions.

Phone: 800-518-4726
Email: support@grants.gov

Sign up on Grants.gov for "send me change notification emails" by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.

VII. APPLICATION SUBMISSION CHECKLIST

Grants.gov Application Components	Action	Completed
SF-424 (R&R) Application for Federal Assistance Form	Complete form as instructed	
Attachments Form	Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1	
	Upload Supporting Documentation (Support.pdf) as Attachment 2	
	Upload Technical Abstract (TechAbs.pdf) as Attachment 3	
	Upload Public Abstract (PublicAbs.pdf) as Attachment 4	
	Upload Statement of Work (SOW.pdf) as Attachment 5	
	Upload Detailed Budget and Justification (Budget.pdf) as Attachment 6	
	Upload Subaward Detailed Budget and Justification (SubBudgets.pdf) as Attachment 7	
	Upload Impact Statement (Impact.pdf) as Attachment 8	
	Upload Transition Plan (Transition.pdf) as Attachment 9	
	Upload Military Relevance Statement (MilRel.pdf) as Attachment 10	
	Upload Human subject plan (HumSub.pdf) as Attachment 11	
	Upload Approval for access to military populations (MilPop.pdf) as Attachment 12	
Research & Related Senior/Key Person Profile (Expanded)	Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field	
	Attach PI Current & Pending Support (Support_LastName.pdf) to the appropriate field	
	Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field	
	Attach Current & Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field	
Project/Performance Site Location(s) Form	Complete form as instructed	